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Abstract 
 
Determination of the Myogenic Potential of Human Embryonic Stem 
Cell-derived Mesenchymal Stem Cells  
 
Rory Coleman, University Scholars Program 
 
University of Connecticut 
2010 
 
 Human embryonic stem cells (hESCs) have the potential to differentiate to all 
adult somatic cells. This property makes hESCs a very promising area of research for the 
treatment of disorders in which specific cell populations need to be restored.  Despite this 
potential, research that focuses on producing mesodermally derived cell populations from 
hESCs is decidedly limited, notwithstanding the prevalence of disorders involving 
mesodermal tissues for which treatment options are limited. Skeletal muscle myoblasts 
are derivatives of mesodermal cells and are characterized by the expression of the MyoD 
gene. These cells are difficult to obtain from hESCs in a reproducible and efficient 
manner. Recent developments in the field have showed some success in obtaining 
myogenic cells from hESCs through a mesenchymal stem cell (MSC)-like intermediate 
population. MSCs, which are an adult stem cell population typically derived from the 
bone marrow, are capable of generating multiple cell types including skeletal muscle. The 
aim of this study was to develop an efficient method that derives myoblasts from an 
MSC-like intermediate. To accomplish this goal, we first set out to isolate and expand the 
MSC-like intermediate from hESCs differentiated in vitro. Difficulties in reproducing 
published cell-differentiation methodologies, which represent a significant and familiar 
challenge in hESC research, are highlighted in this report.  
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Introduction 
I. Human Embryonic Stem Cells 
Human embryonic stem cells (hESCs) are a pluripotent cells with the potential to 
generate all the tissues of the body (Trounson et al, 2006). While ES cells have been 
utilized for years in mouse, it was not until 1998 that Thomson et al. described the first 
successful isolation and cultivation of hESCs (Thomson, et al., 1998). HESCs are derived 
from cells isolated from the inner cell mass (ICM) of the preimplantation blastocyst-stage 
embryo. Following isolation, the ICM cells are plated onto a monolayer of irradiated 
mouse embryonic fibroblast (MEFs) in media supplemented with basic fibroblast growth 
factor (FGF-2). The MEFs and FGF-2 play a critical role in maintaining the ICM cells in 
a pluripotent state (Thomson, et al., 1998). After multiple passages under these 
conditions, the ICM cells take on a characteristic hESC phenotype, forming monolayer 
colonies of cells (Fig. 1) 
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Figure 1. Diagram of the process of deriving human embryonic stem cells from the ICM of blastocysts 
(Winslow & Duckwall, 2001). 
Upon derivation of a new hESC line from an embryo, the cells are characterized 
to verify their pluripotency. The undifferentiated state of a hESC line is characterized by 
the expression of a number of different genes, including cell surface markers such as the 
glycolipid antigens SSEA-3, -4, the keratin sulfate antigens TRA-1-60 and TRA-1-81 
(Ohtsuka & Dalton, 2008), and by transcription factors that play an important role in 
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maintaining the undifferentiated state such as Oct4, Nanog, and Sox2 (Johnson et al, 
2006). Because the expression of only a single marker is insufficient to denote an 
undifferentiated hESC population, the expression pattern of this set of genes is taken 
together to characterize a specific hESC line.  
To confirm pluripotency, cells are shown to be able to differentiate into nearly all 
cell types. This can be accomplished by two means. HESCs can be differentiated as 
embryoid bodies (EBs). Specifically, colonies are isolated from the tissue culture plate 
and grown as units in suspension. These culture conditions cause the hESC cells within 
the colonies to spontaneously aggregate to form spheres. EBs recapitulate the earliest 
stages of embryonic development, in that the three germ layers, endoderm, mesoderm, 
and ectoderm, are formed. Because EBs generate all three germ layers, they serve as an 
important tool for testing the differentiation potential of hESCs (Hwang et al, 2008).  
The second pluripotency test utilized in hESCs is teratoma formation. When 
hESCs are injected into immunodeficient mice they form tumors known as teratomas. 
These teratomas contain randomly differentiated cells of a number of different lineages, 
again serving the important purpose of testing the differentiation potential of the cells 
(Thomson et al, 1998).  
The ultimate test of true pluripotency is the ability of an ESC line to generate a 
complete organism. This is accomplished by injecting ESCs into a developing embryo, 
allowing the embryo to grow to form an adult organism. If the ESCs are contained in the 
germline of the developing embryo then the resulting progeny will be entirely derived 
from the ESC line used in the study. This procedure is routinely used with mouse ESCs, 
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but cannot be used for hESCs due to a number of ethical dilemmas. As a result, hESCs 
can never be shown to be truly pluripotent. 
 In the twelve years since the derivation of the first hESC lines significant progress 
has been made in developing differentiation strategies for the generation of specific 
lineages. HESCs have been shown to readily generate ectodermal lineages, consistent 
with the observation that the ectoderm appears to be a developmental default pathway. 
Furthermore, neurectodermal differentiation, in particular, has proven to be to be 
generated efficiently and is thus, considered to possess significant therapeutic potential 
(Reubinoff et al, 2001). Endodermal lineages have also been derived from hESCs, as 
evidenced by the generation of two clinically important cell types: liver hepatocytes 
(Rambhatla et al, 2003) and insulin-producing  cells (Segev et al, 2004). Unfortunately, 
the in vitro generation of the majority of mesodermal lineages have proven to be much 
more challenging. In addition, the derivation of skeletal muscle from hESCs, the 
mesodermal cell type of interest in this study, has been particularly difficult to 
accomplish. In fact, only a few groups have claimed to be able to differentiate hESCs into 
skeletal muscle. The in vitro differentiation protocols reported by one of these groups is 
examined closely in this study (Barberi et al, 2007). 
 
II. Mesenchymal Stem Cells 
Mesenchymal stem cells (MSCs) are an adult stem cell population that was 
originally isolated from the adult bone marrow and are characterized by their ability to 
adhere to tissue culture plastics. This ability to adhere to tissue culture plates facilitates 
the purification of MSCs away from the hematopoietic stem cells (HSCs) that make up a 
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large portion of the cells of the bone marrow, because HSCs do not adhere to plastic 
(Friedenstein et al, 1978). Importantly, MSCs that were derived in this manner were 
shown to be able to differentiate into mesenchymal (bone associated) cell types.. 
Specifically, MSCs are defined by their ability to differentiate into adipogenic, 
chondrogenic, and osteogenic cell lineages (Pittenger et al, 1999), and, to a lesser extent, 
skeletal muscle (Drost et al, 2009). The ability of these cells to generate such a wide 
variety of cell types highlights their therapeutic potential..  
 Unfortunately, the clinical applications of MSCs is limited by the fact that MSCs 
are difficult to isolate in an efficient manner from the bone marrow and are only capable 
of limited expansion in vitro. It is believed that these limitations can potentially be 
addressed by deriving the MSCs from hESCs instead of the adult bone marrow. In fact, 
multiple studies have recently demonstrated the ability to generate cells from hESCs that 
have an MSC-like phenotype and potential (Lian et al, 2007; Olivier et al, 2006; Trivedi 
& Hematti, 2007).  
MSCs are typically identified by an array of cell surface markers that are 
consistently expressed in MSCs. Again, no single marker can be utilized to identify 
MSCs, but taken together, their expression pattern can be used to define specific cell 
types. The most consistent and well-defined MSC marker profile is CD73-, CD105-, and 
CD90-positivity, as well as CD34- and CD45-negativity (Dominici et al, 2006). HESC-
derived MSCs expressing this profile of markers have been successfully used to derive 
chondrogenic, adipogenic, and osteogenic cell types. Importantly, HESCs offer the 
benefit that they can be expanded indefinitely in culture, thereby offering a possible 
solution to the limited proliferation capacity of bone marrow-derived MSCs.  
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A recent application of this strategic approach demonstrated the potential of 
hESC-derived MSCs to differentiate into skeletal muscle myoblasts (Barberi et al, 2007). 
Although this is a well-characterized property of bone marrow-derived MSCs, it was the 
first report of hESC-derived MSCs. The methodology used by the Barberi group is shown 
in Fig. 2. 
 
Figure 2. Flow chart of the methodology described by Barberi et al. (2007) 
Because the Barberi protocol produced myoblasts at a very low efficiency and 
required long in vitro cell culture conditions (37-38 days), the goal of this study was to 
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modify this protocol with the aim of dramatically increasing the efficiency at which 
skeletal muscle progenitors are obtained.  
To facilitate the identification of MSC-like cells derived from hESCs, we use the 
cell markers CD73 and CD105. CD73 is the Ecto-5’-nucleotidase gene, which functions 
as a purine salvage-pathway enzyme located on the cell’s surface. It catalyzes the 
extracellular dephosphorylation of purine and pyrimidine ribo- and deoxyribonucleoside 
monophosphates to the corresponding nucleosides. Although CD73 is expressed in a 
number of cell types, particularly lymphocytes, it is consistently expressed in MSCs 
(Hansen et al, 1995). CD105 is the endoglin receptor, a part of the transforming growth 
factor- receptor complex (TGF-R). It is expressed in vascular cells and a number of 
blood cell types, and again is a found to be consistently expressed in MSCs (Pierelli et al, 
2001). 
 
III. Skeletal Muscle Development & Regeneration 
 Skeletal muscle begins developing in the embryo primarily from transient 
condensations of paraxial mesoderm that border either side of the neural tube known as 
somites. The dermomyotome is generated within the developing somites, and gives rise 
to the dermis and the skeletal muscle of the trunk and the limbs (Parker et al, 2003). A 
family of genes of known as the Myogenic Regulatory Factors (MRFs) plays an 
important role in controlling myogenic differentiation. Within this group of genes are the 
MyoD and Myf-5 genes. Simultaneous knockout of these two genes gives rise to animals 
devoid of skeletal muscle myoblasts, demonstrating that these genes are necessary for 
skeletal muscle lineage determination (Chen & Goldhamer, 1999).  
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 In adults, skeletal muscle is normally a relatively stable tissue. Following injury-, 
exercise- or disease-induced damage muscle tissue demonstrates an extraordinary 
capacity for regeneration. The muscle stem cell population, known as satellite cells, 
mediates this regenerative process. Satellite cells remain quiescent under the basal lamina 
of adult muscle fibers until damage-induced activation. Upon activation, these cells 
migrate from their niche, upregulate members of the MRF gene family, such as MyoD, 
proliferate, and differentiate to repair the damaged muscle (Fig. 3; Hawke & Garry, 
2001).  
 
Figure 3. Muscle regeneration pathway (Hawke & Garry, 2001) 
 HESCs offer the potential to derive myogenic precursors with the ability to 
repopulate the satellite cell pool. As a possible therapeutic tool, repopulation of the 
satellite cell population could mean a long-term or even a permanent cure to chronic 
muscular disorders. 
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Materials & Methods 
I. hESC Culture 
  All experiments utilize H9 (WA-09, 7D) hESCs of passage 48-60. Cells 
were maintained on matrigel-coated dishes and fed on a daily basis with mouse 
embryonic fibroblast (MEF)-conditioned media (KO-CM). Unconditioned media 
consisted of Knockout DMEM/F12, 10% Knockout Serum Replacement, 1% L-
glutamine, 1% non-essential amino acids, and 4ng/ml bFGF. Media was conditioned by 
culturing mitotically inactivated, irradiated MEFs in T75 flasks with 18ml of 
unconditioned media for 1 day, after which the media was collected and stored at -80˚C 
until used. When used for feeding hESCs the stored media was thawed, and 4ng/ml of 
bFGF was added to make up the final KO-CM. HESCs were mechanically passaged 
every 4-6 days. 
 
II. Gene Expression Analysis 
For RT-PCR analysis, total RNA was extracted from cell samples using the 
Qiagen RNeasy kit and treated with RNase-free DNase I. Primers were designed to be 
intron-spanning so that amplification off genomic DNA produced bands sizes that were 
readily distinguished from those amplified off of mRNA-derived cDNA. PCR annealing 
temperatures were optimized prior to experimental use. 
 
III. Lentiviral Transductions 
Lentivirus for cell transduction studies was prepared by transfecting 293FT cells 
with the reporter construct and RRE, REV, and VSV-G helper plasmids. SuperFect® 
 10 
reagent was used for the transfection of the plasmids. Virus-containing media was 
collected off of the transfected cells once a day for two days. The two viral collections 
were pooled together at the end of the second day and concentrated together using an 
ultracentrifuge at 25,000rpm for 90 minutes. The concentrated virus was then used to 
transduce cells by adding 200µL of the virus to the media for 8-12 hours. 
 
IV. FACS Isolation 
 The FACS experiment was carried out by first washing the experimental cells 
with phosphate buffered saline (PBS) followed by trypsinization of the cells for 3min. 
The trypsin was inactivated using serum-containing media, the cells were washed with 
PBS, and stained with either mouse anti-human CD73 monoclonal antibody 
(BDPharmingen) or purified mouse IgG1,  Isotype control. The cells were then stained 
with the secondary, goat anti-mouse AlexaFluor 633 antibody (Invitrogen). The cells 
were then treated with propidium iodide and filtered through a 100µm mesh prior to cell 
sorting to remove clumps. Cells were sorted and CD73+ and CD73- cells were collected 
and plated on gelatin-coated dishes. 
 
V. MSC Differentiation 
HESCs were trypsinized for 5 minutes and plated at a density of 1000 cells/cm
2
 
onto fibronectin-coated plates (denoted as day -4 experimentally) and cultured in the 
MEF-Conditioned media for 4 days at which point the hESC colonies contained about 50 
cells. At this point (Day 0), experimental cells were transferred to ITS media for 21 days. 
ITS media consists of DMEM/F12 (Invitrogen), 1% Insulin-Transferrin-Selenium (ITS) 
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(Invitrogen), 1% Penicillin/Streptomycin (Invitrogen), and 2.438g/L NaHCO3 (Fisher). 
After the 21 days in ITS media, the cells were transferred to MEM media for an 
additional 7 days. MEM media consists of Alpha MEM (Invitrogen), 10% heat-
inactivated fetal bovine serum (FBS) (Invitrogen), 2mM L-glutamine (Invitrogen), and 
1% Penicillin/Streptomycin. 
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Results 
I. Lentiviral reporter constructs 
 As described in the introduction, the aim of this study was to significantly 
increase the efficiency at which skeletal muscle progenitors can be generated from 
hESCs. In order to achieve this goal we designed a lentiviral reporter system that would 
allow for the identification of cells that had committed to the skeletal muscle lineage. 
Commitment to myogenesis was identified by MyoD expression, a critical muscle 
determination gene described earlier. MyoD expression was monitored through the use of 
the reporter construct containing the MyoD promoter and core enhancer regions (denoted 
as 258/-2.5) driving expression of Cerulean Fluorescent Protein (CFP). Because the 
MyoD promoter and core enhancer regions should reflect normal MyoD expression, cells 
marked by cerulean fluorescence should also express MyoD..  
The construct also contained the constitutively active human elongation factor-1 
(EF1) promoter. EF1 is a highly expressed housekeeping gene that is involved in 
protein synthesis and expressed in all tissue types (Knudsen et al, 1993). In the lentiviral 
reporter construct the EF1  promoter drives the expression of the mCherry Fluorescent 
Protein and a Puromycin resistance gene (Puromycin is an antibiotic that kills both most 
eukaryotic and prokaryotic cells); with the mCherry and Puromycin resistance genes 
being separated by the self-cleaving T2a peptide sequence. Thus, this portion of the 
construct functions with EF1 constitutively driving expression of the mCherry-T2a-
Puromycin protein. Following translation of the fusion protein, the T2a amino acid 
sequence self-cleaves to generate separate mCherry and Puromycin gene products.  
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The constitutive expression of the puromyosin gene product facilitates the 
purification of transduced cells through their ability to grow in media containing 
Puromycin. Additionally, the constitutive mCherry-expression is important for future in 
vivo studies  Specifically, the mCherry-expression would allow for the easy identification 
of cell of hESC origin and allow us to identify the fate of the transplanted cells. The 
bicistronic reporter construct is depicted in Fig. 4. 
 
Figure 4. Map of the bicistronic lentiviral construct. 
HIV LTR 
HIV LTR 
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 The lentiviral construct diagrammed in Fig. 4 denotes two “HIV LTR” sequences 
bordering the reporter sequences. These LTRs enable the genomic integration of  the 
sequence residing between them. 
 The MyoD-CFP-EF1-mCherry lentiviral construct was used to transduce H9 
hESCs. The efficiency of the transduction was low, with only a few successfully 
transduced cells (marked by mCherry fluorescence) per colony. These cells were allowed 
to expand until there were small clusters mCherry+ cells. The cells were then cultured in 
media containing Puromycin. After a few days, the puromycin selection was complete 
and only transduced cells remained in culture.  
While using the MyoD-CFP-EF1-mCherry reporter construct in our cell 
differentiation studies, it was observed that cells lost their mCherry fluorescence upon 
differentiation (Fig. 5Bi & 5Bii). This disappointing finding suggested that the exogenous 
lentiviral EF1 promoter was either being silenced upon differentiation or that the EF1 
promoter is not active in all lineages. This finding negated the usefulness of the reporter 
construct as a constitutive reporter.  
Further characterization of the MyoD-CFP-EF1-mCherry reporter construct also 
revealed problems with the MyoD-CFP portion of the reporter. Because we did not have 
access to a true positive control (MyoD+ cells derived from hESCs) we had to analyze 
the efficacy of the MyoD reporter using other cell types. This was accomplished using 
C2C12 cells, which are a line of immortalized mouse myoblast cells. These cells should 
express MyoD, and moreover, the 258/-2.5 sequence (human MyoD promoter and Core 
Enhancer region) used in the MyoD-CFP-EF1-mCherry reporter construct is known to 
be constitutively expressed in mouse cells (data not shown). However, when C2C12 cells 
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were transduced with the MyoD-CFP-EF1-mCherry reporter construct, no CFP 
fluorescence was observed (Fig. 5). These data demonstrated that the MyoD-CFP-EF1-
mCherry construct was ineffective as both a constitutive reporter and a marker of MyoD 
expression. It is likely that the failure of the 258/-2.5 sequence to report on MyoD 
expression is caused by the close proximity of the strong EF1 and MyoD promoters. 
Because the MyoD-CFP-EF1-mCherry construct could not be utilized for its primary 
purpose, we were forced to redesign the expression construct. 
Hoffman TXRed
CFP
Hoffman mCherry
mCherryHoffman
Ai Aii Bi Bii
Ci Cii Ciii
 
Figure 5. Characterization of the MyoD-CFP-EF1-mCherry construct. (Ai,ii) Images of undifferentiated, 
transduced H9 hESCs. (Bi,ii) Images of serums-differentiated transduced hESCs. Circled spaces 
demonstrate cells that have stopped expressing mCherry fluorescent protein from the EF1 promoter 
(Ci,ii,iii) Images of transduced C2C12 cells. (10X images). 
 Because generation of a new lentiviral reporter system was critical for the 
successful identification of hESC-derived MyoD+ cells, we decided to utilize a two-
vector system in order to avoid the problems associated with a bicistronic reporter 
described above.  One lentiviral construct would serves as a constitutive reporter that 
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maintains its activity in all differentiated lineages, while the second construct will 
successfully recapitulate MyoD expression.  
To solve the problems associated with the silencing of the EF1 promoter, we 
decided to design the new constitutive construct using the CAG promoter instead of the 
EF1 promoter. The CAG promoter is a very strong promoter that contains a modified 
chicken -actin promoter and enhancer elements of the cytomegalovirus (CMV) that has 
shown promise for use in ESCs (Pfeifer et al, 2002). To develop this construct, the CAG 
promoter was excised from a pCAGGS vector and cloned into our lentiviral vector 
backbone. The backbone has a multiple cloning site (MCS) preceding the mCherry-T2a-
Puro sequence, similar to the construct diagrammed in Fig. 4. Because the CAG promoter 
sequence was inserted into the MCS of the lentiviral vector by blunt-end ligation, the 
correct orientation of the CAG promoter was verified. The final CAG-mCherry construct 
can be visualized in Fig. 6.  
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Figure 6. Map of the redesigned constitutive reporter construct. Restriction sites with two cut sites are 
denoted by blue and single cut restriction sites are in orange.  
 To facilitate full characterization of the new constitutive reporter construct, it was 
transduced into H9 hESCs as well as Detroit and Rhabdomyosarcoma (RD) cell lines. 
Additionally, transduced hESCs were differentiated in both serum-containing and ITS 
medium in order to ensure that continual expression of mCherry. The Detroit and RD cell 
lines were selected to ensure that the CAG promoter maintains expression in multiple cell 
types. Detroit cells are a human primary fibroblast line and RD cells are a human skeletal 
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muscle tumor cell line that constitutively expresses MyoD protein. As illustrated in Fig.7, 
the CAG-mCherry construct maintained mCherry expression throughout hESC 
differentiation, as well as in Detroit and RD cells. 
Hoffman mCherry
Hoffman mCherry
mCherry mCherry
mCherry
Hoffman Hoffman
Hoffman
Ai Aii
Bi Bii Ci Cii
EiiEiDiiDi
 
Figure 7. Characterization of the CAG-mCherry constitutive reporter construct. (Ai,ii) Undifferentiated 
transduced H9 hESCs. (Bi,ii) Images of transduced hESCs differentiated in serum-containing media. (Ci,ii) 
Images of transduced hESCs differentiated in ITS-containing media. (Di,ii) Images of transduced Detroit 
cells. (Ei,ii) Images of transduced RD cells (10X images). 
 Because the CAG-mCherry expression was found to be active throughout 
differentiation and in a variety of cell types, the newly designed constitutive reporter will 
allow us to identify cells of hESC origin in future in vivo studies; a feature that  
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was absent in the EF1-mCherry portion of the original bicistronic construct. Cells 
transduced with the newly designed constitutive construct will also need to be transduced 
with a separate MyoD reporter construct that is still under development. Although the use 
of two lentiviral constructs is not ideal because of the increased chance that a construct 
will integrate into a coding region of the host genome, the new strategy will allow us to 
avoid the transcriptional interference caused by proximal promoters. Although the new 
MyoD reporter system was not prepared in time for use in the studies described in this 
report, it will be available for use in future experiments. 
 
II. Differentiation of hESCs into an MSC-like cell type 
 As described in the introduction, the study published by Barberi et al. (2007) is a 
promising protocol for the derivation skeletal muscle from hESCs. The study described 
the generation of skeletal myoblasts from a hESC-derived MSC-like intermediate cell 
population. The MSC-like phenotype was defined by the expression of cell surface 
markers characteristic of bone marrow-derived MSCs: CD166, CD105, CD44, and most 
importantly CD73. The CD73 marker was used to isolate the putative hESC-derived 
MSCs by FACS. The MSC-like nature of the hESC-derived cells was further 
demonstrated by their ability to undergo adipogenic, chondrogenic, and osteogenic 
differentiation.  
As discussed previously, the Barberi protocol was suboptimal because it required 
prolonged culture conditions and yielded skeletal myoblasts at a very  low efficiency. The 
lentiviral reporter construct described above was designed to improve these liabilities. 
Unfortunately, after a number of attempts to replicate this protocol we failed to even 
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duplicate the first step, which required the plating of hESCs at a low-density onto gelatin-
coated dishes (a substrate to which undifferentiated hESCs do not typically attach).  
 Although our inability to duplicate the initial steps of the Barberi protocol 
prevented the use of the original cell differentiation protocol, the Barberi group recently 
published a modified protocol (Stavropoulos et al, 2009). Interestingly, their new 
protocol modified the first step of the cell differentiation protocol. Specifically, the new 
protocol utilized fibronectin-coated dishes rather than gelatin for the initial low-density 
hESC plating step. Importantly, we confirmed that hESCs readily attached to fibronectin-
coated plates. 
 As described in the methods section, the MSC differentiation protocol entails a 3-
4 day hESC attachment step, a 21 day culture step in ITS media, and finally a 7 day 
culture step in MEM media. At this point (day 28) the Barberi group reported the first 
signs of myogenic cells, as evidenced by MyoD expression. Because the generation of 
MyoD+ myoblasts from hESCs is our primary goal, we screened day 28 cultures for the 
presence of MyoD+ cells. The morphology and gene expression signature of the day 28 
cells are shown in Fig. 8 and Fig. 9, respectively. 
 21 
 
A CB
 
Figure 8. Morphology of experimental cells treated according to the Barberi protocol. (A) Image of 
undifferentiated H9 hESCs (4X Hoffman image). (B) Cells after 21 days of culture in ITS media (10X 
Hoffman image). (C) Cells after 21 days in ITS media followed by an additional 7 days of culture in MEM 
media (10X Hoffman image). 
 
 
Figure 9. RT-PCR of experimental cells after 28 days of culture according to the Barberi protocol (1µg of 
RNA was used). 
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 A clear change in cell morphology is evident in hESCs differentiated according to 
the methods described by the modified Barberi protocol (Fig. 8). However, contrary to 
the results reported by Barberi et al., the RT-PCR results shown in Fig. 9 demonstrate 
that MyoD expression is not detected by Day 28 cells. This is a significant finding 
because it means that we cannot use the lentiviral reporter system to isolate MyoD+ cells 
at an earlier stage of the protocol.  
The gene expression analysis depicted in Fig. 9 demonstrates an upregulation of 
the MSC-markers CD73 and CD105, at each time point examined. Surprisingly, CD73 
expression was also observed in undifferentiated hESCs. This observation suggests that 
either hESCs express very low levels of CD73, or that a fraction of hESCs spontaneously 
differentiate into an MSC-like cell type (this would also explain the expression of CD105 
in undifferentiated hESCs).  
 Taken together, these data suggest that while we were not able to get myogenic 
cells utilizing this protocol, it does appear that the protocol works for obtaining MSCs 
from hESCs. Since muscle differentiation is a well-known potential of bone marrow-
derived MSCs, it is possible that these cells may have the same ability. 
 
III. Determination of the Myogenic Potential of hESC-derived MSCs 
  Due to the fact that we were unable to obtain MyoD+ cells by the time point 
Barberi et al. described, we wished to see if we could achieve myogenic differentiation 
from MSC derived by the protocol. Specifically, the modified Barberi protocol was 
utilized in conjunction with CD73 FACS analysis, allowing us to isolate the CD73+, 
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putative MSC-like population. Experimental cells were prepared for FACS isolation of 
the CD73+ at Day 28 of the protocol. The FACS parameter can be seen in Fig. 10. 
Ai
Aii Bii
Bi
Cii
Ci
 
Figure 10. FACS experimental details. (Ai,ii) FACS table and gates for unstained cells. (Bi,ii) FACS table 
and gates for mouse anti-human IgG isotype control antibody. (Ci,ii) Total sort of cells stained with mouse 
anti-human CD73 antibody and with the AlexaFluor 633 goat anti-mouse secondary antibody. 
 The data diagrammed in Fig. 10 shows that after 28 days of culturing hESCs 
according to the modified Barberi protocol yielded only .1% of CD73+ cells.  The 
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staining of cells is shown to be faithful as we did not see any false positives in either the 
unstained or isotype negative controls, although it is possible that there are CD73+ cells 
present in the population that remained unstained. The CD73+ and CD73- were collected 
and plated onto gelatin-coated dishes, the cell numbers are shown in Table 1. 
  
Cells Plated 
Cells 
Attached 
Percentage 
Attached 
Confluence 
Upon RNA-
Extraction 
CD73+ Cells 544 44 8.1% 75-80% 
CD73- Cells 1595 85 5.3% 50-55% 
Table 1. The cell numbers following the CD73 FACS experiment. 
The CD73+ and CD73- cell populations were cultured in MEM media for an 
additional 19 days (cells stopped proliferating before reaching confluency) as per Barberi 
et al.’s instructions for myogenic differentiation (Stavropoulos et al, 2009). As shown in 
Fig. 11, there is a clear morphological distinction between cultures of CD73+ and CD73- 
cells.  
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Figure 11. Morphology of FACS isolated cells following 19 days of expansion in MEM medium. 
The CD73+ cells showed a higher rate of attachment and capacity for 
proliferation than the CD73- population (Table 1). Once the CD73+/- cells stopped 
proliferating, cells were harvested and RNA was extracted for gene expression analysis 
by RT-PCR. The analysis is demonstrated in Fig. 12. 
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Figure 12. RT-PCR of experimental cells after FACS isolation of CD73+/- cells and 19 days of culture in 
MEM media (240ng of RNA; Und.-Undifferentiated H9 hESCs, RD-Rhabdomyosarcoma positive control) 
 Fig. 12 shows that the FACS purification of an MSC-like cell population failed to 
facilitate the isolation of MyoD+ cells. It should be noted that for terminal myogenic 
differentiation the Barberi group also included a sort for NCAM+ cells to select for 
myogenic cells within the MSC population, prior to differentiation. Despite this 
observation, we still expected to see MyoD expression without the NCAM sort as the 
Barberi group reported MyoD expression by day 28 of their protocol, a time point that 
proceeds our CD73 sort. The CD73+ population did have the appearance of a true MSC 
population, with robust CD73 and CD105 expression. Interestingly, the CD73- 
population showed expression of CD73 and CD105. This could be explained by the fact 
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that not all the CD73+ cells were labeled during the FACS isolation (discussed earlier) or 
that a portion of the CD73- cells had the potential to differentiate into an MSC-like 
population and did so in the MEM medium. 
 It is unfortunate that the methods published by the Barberi group have thus far 
proven to be very difficult to replicate. Our studies have shown no sign of myogenic 
potential in these cells. Despite this, the protocol does appear to have promise in 
producing MSC from hESCs, which may have the potential to form skeletal muscle if 
alternative approaches are taken. 
 28 
 
Discussion 
 Derivation of skeletal muscle from ESCs is an area of research that has shown 
little progress since the first hESCs were derived. Success has been made in mouse 
embryonic stem cells (mESCs) using a variety of strategies. Groups have successfully 
obtained skeletal muscle from mESCs by transducing with vector systems expressing 
MyoD in a transient (Craft et al, 2008) or inducible manner (Ozasa et al, 2007). 
Alternatively, mESCs have been induced to undergo myogenic differentiation by 
culturing the mESCs as EBs in FBS-containing media supplemented with spermine 
analogs (Sasaki et al, 2008) or with horse serum (Chang et al, 2009). Utilizing what is 
known from mESC research, which has been going on for decades, is the logical choice 
for directing hESC studies. Unfortunately, these differentiation strategies have not been 
able to be translated to hESCs. This problem of mESC research not fully applying to 
hESC research is most likely related to the fact that mESCs and hESCs exhibit largely 
different behavior. For example, mESCs require leukemia inhibitory factor (LIF) to 
maintain a pluripotent state while hESCs require FGF, bone morphogenic protein (BMP) 
is another cytokine important in maintaining the pluripotent state of mESCs, but in 
hESCs it is a potent inducer of differentiation, and furthermore, pluripotent mESCs and 
hESCs are identified by a number of different genes. These critical differences between 
mESCs and hESCs calls into question whether or not these two cell types actually 
represent cells of the same developmental stage and could potentially explain the inability 
to use mESC experimental protocols to achieve the same results with hESCs. 
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 Due to the difficulties described above in translating mESC research to hESCs, 
hESCs studies have had to discover novel cellular differentiation strategies. In 2006 the 
first group published results showing the ability to generate cells expressing myogenic 
markers in vitro (Zheng et al, 2006). This study grew hESCs as EBs, plated the EB-
differentiated cells, and cultured the outgrowths from the plated EBs in media 
supplemented with FBS, dexamethasone, ITS, and epidermal growth factor (EGF). This 
treatment produced cells expressing myogenic markers, including MyoD, after two weeks 
of culture. Despite the successes of this protocol, it had may short comings, including a 
very low efficiency of obtaining myogenic cells and an inability for the cells to undergo 
terminal differentiation and form myotubes and myofibers. This inability to obtain more 
maturely differentiated cells is a typical problem in ESC research, which frequently can 
generate more embryonic or fetal cell types, rather than the cells more characteristic of 
the adult organism. While our reporter system could potentially greatly increase the 
efficiency of this protocol, the limitations in cellular differentiation made undesirable for 
our purposes. 
 Very recently a publication came describing a new means for obtaining skeletal 
muscle from hESCs. This protocol generated myogenic cells by culturing as EBs and 
treating them serum-free media containing SB-431542, a small molecule inhibitor of the 
TGF-/Activin/Nodal signaling pathway (Mahmood et al, 2010). As previously 
described, EB formation leads to the generation of endodermal, mesodermal, and 
ectodermal lineages. The study showed that SB-431542-mediated inhibition of TGF-
/Activin/Nodal signaling led to a decrease in the ability of the EBs to form endodermal 
cells types while a dramatic increase in the ability of the cells to form muscle cell types, 
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including skeletal muscle, at fairly high efficiency (52% of experimental cells expressed 
MyoD). This study is not only promising in its ability to produce skeletal muscle, but also 
in the information it provides about the nature of hESC differentiation. The fact skeletal 
muscle has proven so difficult to obtain from hESC, and yet are generated relatively 
easily and in abundance once endodermal differentiation is blocked suggests that 
difficulty in forming mesodermal cell types is a preferences of hESCs to differentiate into 
endodermal lineages. While our experiments did not include any analysis of endodermal 
differentiation, it is very possible that this is the lineage that cells progressed down, 
explaining our inability to generate myogenic cells Blocking endodermal with small 
molecule inhibitors, like the one used in this study, or by other may be critical in 
advancing hESCs research so that historically difficult to generate mesodermal cell types 
can be formed. 
Unfortunately, at the beginning of this study the findings of Mahmood et al. were 
not yet published, and thus, Barberi’s publication in 2007 regarding a protocol that 
supported the in vitro differentiation of skeletal myoblasts capable of terminal 
differentiation from hESCs (Barberi et al, 2007) was viewed as a major development. 
Although the cell differentiation protocol was inefficient and required a prolonged time in 
cell culture, the protocol did offer a simple, stepwise methodology for generating skeletal 
muscle. The original goal of this study was to modify the protocol provided by Barberi et 
al. using a lentiviral reporter system to enhance the ability to derive myoblasts from 
hESCs. Unfortunately, the original MyoD-CFP-EF1-mCherry reporter we generated for 
this study had to be redesigned (Fig. 5) because of unacceptable limitations. While the 
modified reporter system may eventually facilitate the efficient isolation of myogenic 
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cells, our results suggest that that the Barberi protocol cannot be used for obtaining 
MyoD+ cells in a reproducible manner. 
 HESC research is beset with issues of reproducibility due to a lack of 
standardization in the field. Different labs utilize a variety of genetically diverse lines that 
may exhibit differences in potentiality or preferred lineages of differentiation. 
Additionally, hESCs are cultured under a variety of different culture conditions. For 
example, labs may culture their hESCs on feeder layers such as irradiated mouse 
embryonic fibroblasts (MEFs) or on irradiated human fibroblasts. There are also feeder-
free culture systems, in which hESCs are cultured on matrigel or fibronectin and fed with 
MEF-conditioned media or chemically defined media known as mTeSR. It is reasonable 
to assume that culturing hESCs on other cell types or in different culture mediums could 
very well affect the potential of these cells. This is an important issue that could provide a 
potential explanation for our inability to replicate the results of the Barberi group. 
Specifically, Barberi et al. culture their cells on MEFs, whereas we wished to avoid 
contamination of our cells with mouse contaminants and therefore cultured our hESCs on 
matrigel with MEF conditioned media. The MEFs utilized by the Barberi group may have 
provided a lineage commitment that accounts for their ability to form myoblasts. This is 
the most probable cause for our inability to reproduce Barberi et al.’s results, as it is one 
of the few variables existing between their methods and ours that could potentially have a 
significant influence. 
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 While MSC-like cells were derived using this protocol, the efficiency of their 
derivation was fairly low. While the Barberi group did not report the percentage of cells 
that they obtained that were CD73+, our percentage was only 0.1% (Fig. 10). 
The results outlined in this report showed that CD73 is actually being expressed 
in undifferentiated hESCs (Fig. 12). As previously discussed, this suggests that there may 
be a small population of spontaneously differentiated MSCs within hESC colonies. This 
information could potentially be useful if MSCs could be efficiently derived directly from 
undifferentiated hESCs using a CD73 reporter system or other strategy. 
 We failed to detect MyoD expression  at any point during differentiation. 
Although Barberi et al. reported the appearance of MyoD gene expression by Day 28 of 
their protocol, we could not reproduce this result, even after the expansion and 
differentiation of the CD73+ cells. However, it may be possible to obtain myogenic cells 
from the MSC-like cells using more established differentiation methods.  
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Future Directions 
 Immediate experimental goals would be to improve upon the Barberi group’s 
methodology for obtaining myogenic cells from their CD73+ MSC-like cell population. 
Barberi et al. utilized MEM media containing 10% fetal bovine serum to differentiate 
their hESC-derived MSCs into skeletal muscle. This is not a differentiation medium 
typically used to obtain skeletal muscle from MSCs. Bone marrow-derived MSCs, which 
have been studied for significantly longer than hESC-derived MSCs, are most typically 
differentiated into muscle in vitro using media supplemented with 20% FBS, 0.5% 
chicken embryo extract, and 10% horse serum (Pozzobon et al, 2008). Another study 
transduced bone marrow-derived MSCs using a retroviral system expressing Pax3 
showed significant skeletal muscle differentiation (Gang et al, 2008). This protocol had 
the advantage over the Pozzobon study, in that they were capable of generating myogenic 
cells capable of terminal differentiation without the use of non-physiological agents such 
as 5-azacytidine. Using these strategy or possibly another, such as co-culture with C2C12 
cells, it may be possible to successfully derive myogenic cells from the MSCs obtained 
by the Barberi protocol. If these techniques proved successful then the lentiviral reporter 
systems could be utilized in improving the efficiency of a new protocol. 
 For longer-term experimental design, the study published by Mahmood et al. 
offers important direction for developing future mesodermal differentiation strategies. 
One of the limitations of the Mahmood study was that it relied on EB formation for the 
initial stages of differentiation. As described previously, EB differentiation spontaneously 
generates all three germ layers. The difficulties in using such a strategy are that, even 
when a lineage inhibitor (like SB-431542) is used, the EBs generate a heterogeneous cell 
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population. For a protocol to be truly useful for clinical applications it would ideally 
allow for the directed, homogeneous differentiation of hESCs into the cell type of 
interest. This means that the best differentiation strategies would avoid random and 
heterogeneous differentiation steps such as those involved in EB formation. Therefore, 
future experiments should focus on utilizing the strategy of lineage restriction shown by 
Mahmood et al. to obtain skeletal myoblasts in a directed manner. Mimicking the signals 
known from embryonic development is the most logical approach to directing the 
differentiation of hESCs. By utilizing BMP-4, a known inducer of mesoderm in hESCs 
(Zhang et al, 2008), to generate a primitive mesodermal cell population followed by 
treatment with cytokines known to induce skeletal muscle development such as Wnt3a 
and Wnt7a (Parker et al, 2003). This strategy has been attempted previously in our lab, 
unsuccessfully, but with the lineage restriction provided by TGF-/Activin/Nodal 
signaling pathway inhibition via the SB-431542 inhibitor could allow for the intended 
mesodermal differentiation due to the blocked default endodermal lineage. 
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